Alliance portfolio R&D intensity and new product introduction

Abstract

Purpose -The purpose of this paper is to examine whether alliance portfolio R&D intensity contributes to biopharmaceutical firms' number of new product approvals and whether alliance portfolio R&D intensity is more positively related to the number of new product approvals for pharmaceutical firms than for biotechnology firms. Design/methodology/approach -The paper employs a random effects Poisson regression model using panel data of 821 firm year observations for 146 biopharmaceutical firms operating in the USA. The robustness of results is also checked with additional analysis, provided in an appendix. Findings -The results of this study show that the R&D intensity of firms' alliance portfolios is positively related to their new product introductions. It is also found that alliance portfolio R&D intensity has a more positive impact on the pharmaceutical segment of the industry's new product introductions than those of the biotechnology segment. Originality/value -The authors develop and test theory about how the combined effects of two dimensions of alliance portfolio configuration (size and relationship strength) positively impact new product development. The authors propose a two dimensional alliance portfolio configuration measure, alliance portfolio R&D intensity. They combine the number of R&D alliances relative to the total number of alliances in the portfolio with the differential strength of ties associated with resource commitments required to source information from upstream and downstream alliances.

Ensuring Competitive Advantage through Innovation Capability and Clustering in the Thai Automotive Parts Molding Industry: A SEM Approach

“…Joint ventures (JVs) also permit the partners to share the risks and costs, while giving easier access to resources such as technical expertise, technology and financing. A JV can also greater flexibility to the members and the ability to react to market conditions quicker [32,[39][40][41].…”

Partner Type Diversity in Alliance Portfolios: Multiple Dimensions, Boundary Conditions and Firm Innovation Performance

“…Our investigation of partner type diversity addresses two important gaps in this line of research on alliance portfolios. First, so far extant studies have investigated specific types of diversity (for instance, partner type diversity) in terms of single dimensions or measures (Caner and Tyler, 2013;Jiang et al, 2010;Van de Vrande, 2013). We argue that it is imperative to adopt a multidimensional perspective of partner type diversity.…”

The Impact of Strategic Alliance Partner Characteristics on Firms’ Innovation: Evidence from Jordan

“…These results suggest the benefits of network "closure" (wherein a firm's partners are also partners) and access to diverse information can coexist in an alliance network and that these combined benefits increase exploratory innovation. Caner and Tyler (2013) in their study investigated the contribution of alliance portfolio R&D intensity to the firm's number of new products introduced; the study found that the R&D intensity of alliance portfolio related to the firm products innovations and introductions, also the study found that the R&D intensity of alliance portfolio has a more positive impact on the pharmaceutical companies new products innovation and introduction than those of biotechnology companies. Zheng, Li and Wu (2013) investigated the correlation between network resources and innovation performance of Chinese manufacturing firms, the study found that there is a direct contribution of network resources to firm's innovation performance.…”